Eisai CEO Haruo Naito Appointed Knight Commander of British Empire
Tokyo, Apr 15, 2014 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo,
President & CEO: Haruo Naito, "Eisai") announced today that in
recognition of his valuable contribution to relations between Britain and
Japan, Her Majesty Queen Elizabeth II has appointed Dr. Haruo Naito, President
& CEO of Eisai Co., Ltd. to be an Honorary Knight Commander of the Order of
the British Empire (KBE).
The Honorary Knight Commander of the Order of the British Empire (KBE) award
recognizes excellent achievement in a wide variety of fields and appreciates
contributions to greater society, and is especially awarded to people who have
left behind significant accomplishments, or people who have dedicated
themselves to social services.
Statement from the British Embassy
Dr. Naito has continued to demonstrate steadfast commitment to the U.K. and
Europe, acting as de facto figurehead for the British Government's
campaign to attract investment from the Japanese life sciences industry. The
most striking evidence of his championing of the U.K. is the GBP100 million
investment in 2009
to build the European Knowledge Centre in Hatfield as Eisai's strategic
base in Europe. Since then the company has further extended the British base to
support its growing European, African and Middle Eastern business, and opened a
new solid dose global manufacturing line for the anti-epileptic agent Fycompa
in Hatfield in 2012. The company also continues to conduct ground-breaking
development in the U.K., including via its long-standing collaboration with
University College London, with whom the company has an alliance to develop
therapeutics for neurological disease.
Comment from Dr. Naito
It is a great honor to be appointed Honorary Knight Commander of the Order of
the British Empire (KBE). Since Eisai established its first European office in
London in 1988, we have built a strong relationship with the U.K. throughout
the course of a quarter of a century. In 1990, Eisai established the Eisai
London Research Laboratories at the University College London in the U.K., and
has made many accomplishments through the exchange of knowledge and experience
between leading scientists from the U.K. and Japan. In 2009, Eisai established
the European Knowledge Centre, which integrates the company's European
headquarters, research & development, production and marketing functions
into one site, in Hatfield. Currently, it looks beyond Europe to the Middle
East, Africa and Australia as well, and forms one of our primary global
business units. Together with strengthening the positive mutual trust we have
cultivated between Japan and the U.K. until now, we intend to take this honor
as a further impetus to
realize the creation of innovative new medicines based on Britain's
world-leading life science infrastructure, and make an even greater
contribution to global health and welfare.
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care
(hhc) company that discovers, develops and markets products throughout the
world. Eisai focuses its efforts in three therapeutic areas: integrative
neuroscience, including neurology and psychiatric medicines; integrative
oncology, which encompasses oncotherapy and supportive-care treatments; and
vascular/immunological reaction. Through a global network of research
facilities, manufacturing sites and marketing subsidiaries, Eisai actively
participates in all aspects of the worldwide healthcare system. For more
information about Eisai Co., Ltd., please visit www.eisai.com.
Public Relations Department,
Eisai Co., Ltd.
Copyright 2014 JCN Newswire. All rights reserved. www.japancorp.net
Provider ID: 00029021
Press spacebar to pause and continue. Press esc to stop.